The £47m centre on Imperial College London's Hammersmith Hospital campus has carried out GSK-dedicated research in close collaboration with academic researchers since it opened in 2007. Housing an advanced radiochemistry development facility, two MRI machines and two PET scanners, the centre focuses on the development and application of imaging techniques for clinical research.
Under the new research alliance, the expertise of the four partners will help to drive the centre into new areas and applications of imaging.
"This agreement is further evidence of the (biomedical) industry shifting towards a more open model of working. Combining the knowledge and expertise that each party brings to the new centre will foster innovation in this exciting area of research, and the industry as a whole stands to benefit from these new imaging opportunities" said Dr Patrick Vallance, Head of Medicines Discovery and Development at GSK.
Modern imaging technology allows the study of disease processes in fine detail and to measure the action of medicines in human organs such as the brain and heart. Its unparalleled sensitivity allows interactions to be probed at the molecular level. PET imaging is already widely used as a cancer diagnostic and is increasingly being used in research to develop new treatments in cancer, heart and brain disorders and inflammation.
Imperial Consultants have worked closely with GSK and the biomedical industry on a number of consultancy projects involving testing and analysis using the Centre's top class facilities.
To access the technical know-how of medical imaging specialists working at the centre, and across the College in the area of clinical medicine, please contact us.
To find out more about this story please see Imperial College's News and Events.